Next Article in Journal
Chest Imaging of Patients with Sarcoidosis and SARS-CoV-2 Infection. Current Evidence and Clinical Perspectives
Previous Article in Journal
Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts
Article

COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications

1
National Institute for Health Research (NIHR) Innovation Observatory, Newcastle University, Newcastle NE4 5TG, UK
2
Evidence Synthesis Group, Population Health Sciences Institute, Newcastle University, Newcastle NE2 4AX, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Mario Cruciani
Diagnostics 2021, 11(2), 182; https://doi.org/10.3390/diagnostics11020182
Received: 18 December 2020 / Revised: 22 January 2021 / Accepted: 25 January 2021 / Published: 27 January 2021
(This article belongs to the Section Diagnostic Microbiology and Infectious Disease)
Diagnostic testing remains the backbone of the coronavirus disease 2019 (COVID-19) response, supporting containment efforts to mitigate the outbreak. The severity of this crisis and increasing capacity issues associated with polymerase chain reaction (PCR)-based testing, accelerated the development of diagnostic solutions to meet demands for mass testing. The National Institute for Health Research (NIHR) Innovation Observatory is the national horizon scanning organization in England. Since March, the Innovation Observatory has applied advanced horizon scanning methodologies and tools to compile a diagnostic landscape, based upon data captured for molecular (MDx) and immunological (IDx) based diagnostics (commercialized/in development), for the diagnosis of SARS-CoV-2. In total we identified and tracked 1608 diagnostics, produced by 1045 developers across 54 countries. Our dataset shows the speed and scale in which diagnostics were produced and provides insights into key periods of development and shifts in trends between MDx and IDx solutions as the pandemic progressed. Stakeholders worldwide required timely and detailed intelligence to respond to major challenges, including testing capacity and regulatory issues. Our intelligence assisted UK stakeholders with assessing priorities and mitigation options throughout the pandemic. Here we present the global evolution of diagnostic innovations devised to meet changing needs, their regulation and trends across geographical regions, providing invaluable insights into the complexity of the COVID-19 phenomena. View Full-Text
Keywords: COVID-19; SARS-CoV-2; diagnostic tests; IVDs; immunoassays; rapid diagnostic tests; molecular assays; horizon scanning COVID-19; SARS-CoV-2; diagnostic tests; IVDs; immunoassays; rapid diagnostic tests; molecular assays; horizon scanning
Show Figures

Figure 1

MDPI and ACS Style

Oyewole, A.O.; Barrass, L.; Robertson, E.G.; Woltmann, J.; O’Keefe, H.; Sarpal, H.; Dangova, K.; Richmond, C.; Craig, D. COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications. Diagnostics 2021, 11, 182. https://doi.org/10.3390/diagnostics11020182

AMA Style

Oyewole AO, Barrass L, Robertson EG, Woltmann J, O’Keefe H, Sarpal H, Dangova K, Richmond C, Craig D. COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications. Diagnostics. 2021; 11(2):182. https://doi.org/10.3390/diagnostics11020182

Chicago/Turabian Style

Oyewole, Anne O., Lucy Barrass, Emily G. Robertson, James Woltmann, Hannah O’Keefe, Harsimran Sarpal, Kim Dangova, Catherine Richmond, and Dawn Craig. 2021. "COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications" Diagnostics 11, no. 2: 182. https://doi.org/10.3390/diagnostics11020182

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop